General
Preferred name
ELETRIPTAN
Synonyms
ELETRIPTAN HYDROBROMIDE ()
Eletriptan HBr ()
UK-116044 ()
[3H]eletriptan ()
Eletriptan (hydrobromide) ()
UK-116044 (hydrobromide) ()
NSC-759258 ()
Relpax ()
UK-116,044-04 ()
UK-116044-04 ()
UK-116,044 ()
UK-116044-04 FREE BASE ()
UK-116,044-04 FREE BASE ()
[3H]eletriptan ()
P&D ID
PD010168
CAS
143322-58-1
177834-92-3
Tags
available
drug
drug candidate
Approved by
FDA
First approval
2002
Drug indication
Discovery agent
Migraine
migraine disorder
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Eletriptan hydrobromide (Eletriptan HBr) is a 5-HT1B and 5-HT1D receptor agonist with antimigraine activity, with Ki of 0.92 nM and 3.14 nM, respectively[1][2][3][4][5][6].
PRICE 62
DESCRIPTION Approved as eletriptan hydrobromide. (GtoPdb)
MOA Eletriptan binds with high affinity to 5-HT1B, 5-HT1D and 5-HT1F receptors, has modest affinity for 5-HT1A, 5-HT1E, 5-HT2B and 5-HT7 receptors, and little or no affinity for 5-HT2A, 5-HT2C, 5-HT3, 5-HT4, 5-HT5A and 5-HT6 receptors. In contrast, eletriptan displays insignificant pharmacological activity at adrenergic alpha1, alpha2, or beta; dopaminergic D1 or D2; muscarinic; or opioid receptors. While the full mechanism of action of 5-HT receptor agonists in relieving migrains is not fully elucidated, it is proposed that the activation of 5-HT1 receptors located on intracranial blood vessels leads to vasoconstriction that correlates with the relief of migraine headaches. It is also proposed that the activation of 5-HT1 receptors on sensory nerve endings in the trigeminal system leads to the inhibition of release of pro-inflammatory neuropeptides.
PRICE 195
DESCRIPTION Eletriptan, second-generation triptans used to treat migraines, is used as an abortion drug.
DESCRIPTION Orally active, selective 5-HT1B/1D agonist (Tocriscreen Plus)
DESCRIPTION Orally active, selective 5-HT1B/1D agonist (Tocriscreen Total)
DESCRIPTION Eletriptan hydrobromide (Eletriptan HBr) is an orally active agonist with specific affinity for the 5-hydroxytriptamine1B/1D [5-HT1B/1D] receptor. (TargetMol Bioactive Compound Library)
Compound Sets
30
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Concise Guide to Pharmacology 2025/26
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP Approved Drugs
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NPC Screening Collection
Other bioactive compounds
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Tocriscreen Plus
Tocriscreen Total
External IDs
91
Properties
(calculated by RDKit )
Molecular Weight
382.17
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
1
Rotatable Bonds
6
Ring Count
4
Aromatic Ring Count
3
cLogP
3.82
TPSA
53.17
Fraction CSP3
0.36
Chiral centers
1.0
Largest ring
6.0
QED
0.71
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target Type
7-TM Receptors
Target
5-HT Receptor
5-HT1B
5-HT1D
HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR7
5-HT1B/1D agonist
Indication
migraine headache
MOA
serotonin receptor agonist
Therapeutic Class
Antimigraine Agents
Pathway
GPCR/G protein
Neuronal Signaling
Neuroscience
Source data